KR102265159B1 - 수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도 - Google Patents

수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도 Download PDF

Info

Publication number
KR102265159B1
KR102265159B1 KR1020197028654A KR20197028654A KR102265159B1 KR 102265159 B1 KR102265159 B1 KR 102265159B1 KR 1020197028654 A KR1020197028654 A KR 1020197028654A KR 20197028654 A KR20197028654 A KR 20197028654A KR 102265159 B1 KR102265159 B1 KR 102265159B1
Authority
KR
South Korea
Prior art keywords
patients
hcc
medicament
involvement
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197028654A
Other languages
English (en)
Korean (ko)
Other versions
KR20190120339A (ko
Inventor
스탠리 창
콴-랑 라이
Original Assignee
메디젠 바이오테크놀로지 코프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디젠 바이오테크놀로지 코프 filed Critical 메디젠 바이오테크놀로지 코프
Publication of KR20190120339A publication Critical patent/KR20190120339A/ko
Application granted granted Critical
Publication of KR102265159B1 publication Critical patent/KR102265159B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197028654A 2017-03-01 2018-02-24 수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도 Active KR102265159B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762465170P 2017-03-01 2017-03-01
US62/465,170 2017-03-01
US201762504552P 2017-05-11 2017-05-11
US62/504,552 2017-05-11
US201762551770P 2017-08-29 2017-08-29
US62/551,770 2017-08-29
PCT/CN2018/077105 WO2018157762A1 (en) 2017-03-01 2018-02-24 Use of sulfated oligosaccharides in the manufacture of a medicament for treating patients with hepatocellular carcinoma after surgical resection

Publications (2)

Publication Number Publication Date
KR20190120339A KR20190120339A (ko) 2019-10-23
KR102265159B1 true KR102265159B1 (ko) 2021-06-17

Family

ID=63357147

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028654A Active KR102265159B1 (ko) 2017-03-01 2018-02-24 수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도

Country Status (6)

Country Link
US (1) US10842804B2 (enExample)
JP (1) JP6948080B2 (enExample)
KR (1) KR102265159B1 (enExample)
CN (1) CN110381953A (enExample)
TW (1) TWI693071B (enExample)
WO (1) WO2018157762A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113160911A (zh) * 2021-02-26 2021-07-23 杭州臻合健康科技有限公司 一种用于术前肝功能耐受性分析的评估系统
CN117476246B (zh) * 2023-12-25 2024-04-19 福建大数据一级开发有限公司 基于多类型复发事件的患者生存分析方法、介质及装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167434A1 (zh) 2011-06-09 2012-12-13 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875592B2 (en) * 2004-03-04 2011-01-25 Progen Pharmaceuticals Limited Sulfated oligosaccharide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167434A1 (zh) 2011-06-09 2012-12-13 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Hepatology, Vol. 50, pp. 958-968 (2009)*
Journal of International Pharmacoceutical Research, Vol. 35, No. 6, pp. 411-414 (2008)

Also Published As

Publication number Publication date
KR20190120339A (ko) 2019-10-23
TWI693071B (zh) 2020-05-11
JP2020509035A (ja) 2020-03-26
JP6948080B2 (ja) 2021-10-13
US10842804B2 (en) 2020-11-24
US20180250317A1 (en) 2018-09-06
WO2018157762A1 (en) 2018-09-07
TW201840324A (zh) 2018-11-16
CN110381953A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
US20250154274A1 (en) Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
Camidge et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing advanced nonsquamous EGFR-wildtype non–small cell lung cancer in the phase II LUMINOSITY trial
Powles et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
UA126970C2 (uk) Комбінації кабозантинібу і атезолізумабу для лікування раку
Sharp et al. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
JP2013067645A (ja) 転移性乳癌の治療
CN108602892A (zh) 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌
CN119923259A (zh) 治疗具有激活型fgfr3基因改变的实体瘤的方法
Akamatsu et al. Pembrolizumab plus amrubicin in patients with relapsed SCLC: multi-institutional, single-arm phase 2 study
KR102265159B1 (ko) 수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도
Harbeck et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
Prawira et al. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)
US12454573B2 (en) Dosages of emactuzumab
CN120731227A (zh) 使用抗ctla4抗体治疗结直肠癌的方法
Stefanou et al. Subcutaneous trastuzumab combined with pertuzumab and docetaxel as first-line treatment of advanced HER2-positive breast cancer
Cui et al. Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study
Tang et al. Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients
Zeng et al. Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study
KR20240162547A (ko) 화학요법과 조합하여 항-pd-l1 항체를 사용하여 담도암을 치료하는 방법
TW202529802A (zh) 胃癌和／或胃食管結合部癌的治療
Kashiwagi et al. Masatsune Shibutani1✉, Hideki Tanda1, Hiroaki Kasashima1, Tatsunari Fukuoka1
WO2025179012A1 (en) Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
DEVELOPM Drug DeveloPment
Leemans Short title NeoNivo EudraCT number 2018-002643-28 Version 9 Date 11-12-2019 Principal investigators C. Willemien Menke-van der Houven van Oordt, MD PhD
Schmid et al. Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200513

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20200612

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200717

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201129

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210427

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210609

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210610

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250610

Start annual number: 5

End annual number: 5